Hemophilia Treatment Drugs Market by Disease Indication, Product Type, and Distribution Channel - Global Industry Analysis & Forecast to 2027
Published On : September 2019 Pages : 142 Category: Next Generation Technology Report Code : IC095844
Hemophilia Treatment Drugs Market by Disease Indication (Hemophilia A, Hemophilia B, Others) Product Type (Recombinant Coagulation Factor Concentrates, Plasma derived Coagulation Factor Concentrates) Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The hemophilia treatment drugs market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Treatments for hemophilia include receiving clotting factors replacement therapy, medication, and treatment for joint bleeding and other problems associated with hemophilia. Several different types of clotting factors are related with various assortments of hemophilia. Hemophilia is a complex disorder. Great quality medicinal consideration from specialists and attendants who know a lot about the disorder can help individuals with hemophilia avoid some difficult issues. The hemophilia treatment center provides patients with the consideration and training to deliver all issues that are related to the disorder.
Drivers and Restraints
Government initiatives and support in the treatment of hemophilia drives the growth of hemophilia treatment drugs market. Huge investment by manufacturers on drugs for the treatment of hemophilia propels the growth of hemophilia treatment drugs market. Growing demand for long-acting replacement therapies fuels the growth of hemophilia treatment drugs market. Less awareness in people and high cost of treatment may hamper the growth of hemophilia treatment drugs market. Rapid advancement in gene therapy provides beneficial opportunities for the hemophilia treatment drugs market.
Regional Insights
Among the geographies, North America is expected to dominate the hemophilia treatment drugs market. Huge investment in healthcare industry in the region contribute to the growth of hemophilia treatment drugs market.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Bayer AG
- Swedish Orphan Biovitrum AB.
- Pfizer Inc.
- Biogen Idec, Inc.
- Baxter International Inc.
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Hemophilia Treatment Drugs Market, By Disease Indication, Estimates and Forecast, 2017-2027 ($Million)
o Hemophilia A
o Hemophilia B
o Other
· Hemophilia Treatment Drugs Market, By Product Type, Estimates and Forecast, 2017-2027 ($Million)
o Recombinant Coagulation Factor Concentrates
o Plasma derived Coagulation Factor Concentrates
· Hemophilia Treatment Drugs Market, By Distribution Channel, Estimates and Forecast, 2017-2027 ($Million)
o Retail Pharmacies
o Hospital Pharmacies
o Online Pharmacies
· Hemophilia Treatment Drugs Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Bayer AG
o Swedish Orphan Biovitrum AB.
o Pfizer Inc.
o Biogen Idec, Inc.
o Baxter International Inc.
· Hemophilia Treatment Drugs Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Hemophilia Treatment Drugs Market, By Country
o U.S. Hemophilia Treatment Drugs Market
o Canada Hemophilia Treatment Drugs Market
o Mexico Hemophilia Treatment Drugs Market
o Europe
§ Europe Hemophilia Treatment Drugs Market, By Country
o Germany Hemophilia Treatment Drugs Market
o UK Hemophilia Treatment Drugs Market
o France Hemophilia Treatment Drugs Market
o Russia Hemophilia Treatment Drugs Market
o Italy Hemophilia Treatment Drugs Market
o Rest of Europe Hemophilia Treatment Drugs Market
o Asia-Pacific
§ Asia-Pacific Hemophilia Treatment Drugs Market, By Country
o China Hemophilia Treatment Drugs Market
o Japan Hemophilia Treatment Drugs Market
o South Korea Hemophilia Treatment Drugs Market
o India Hemophilia Treatment Drugs Market
o Southeast Asia Hemophilia Treatment Drugs Market
o Rest of Asia-Pacific Hemophilia Treatment Drugs Market
o South America
§ South America Hemophilia Treatment Drugs Market
o Brazil Hemophilia Treatment Drugs Market
o Argentina Hemophilia Treatment Drugs Market
o Columbia Hemophilia Treatment Drugs Market
o Rest of South America Hemophilia Treatment Drugs Market
o Middle East and Africa
§ Middle East and Africa Hemophilia Treatment Drugs Market
o Saudi Arabia Hemophilia Treatment Drugs Market
o UAE Hemophilia Treatment Drugs Market
o Egypt Hemophilia Treatment Drugs Market
o Nigeria Hemophilia Treatment Drugs Market
o South Africa Hemophilia Treatment Drugs Market
o Rest of MEA Hemophilia Treatment Drugs Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Hemophilia Treatment Drugs Market, By Disease Indication
5.1. Introduction
5.2. Global Hemophilia Treatment Drugs Revenue and Market Share by Disease Indication (2017-2027)
5.2.1. Global Hemophilia Treatment Drugs Revenue and Revenue Share by Disease Indication (2017-2027)
5.3. Hemophilia A
5.3.1. Global Hemophilia A Revenue and Growth Rate (2017-2027)
5.4. Hemophilia B
5.4.1. Global Hemophilia B Revenue and Growth Rate (2017-2027)
5.5. Other
5.5.1. Global Other Revenue and Growth Rate (2017-2027)
6. Hemophilia Treatment Drugs Market, By Product Type
6.1. Introduction
6.2. Global Hemophilia Treatment Drugs Revenue and Market Share by Product Type (2017-2027)
6.2.1. Global Hemophilia Treatment Drugs Revenue and Revenue Share by Product Type (2017-2027)
6.3. Recombinant Coagulation Factor Concentrates
6.3.1. Global Recombinant Coagulation Factor Concentrates Revenue and Growth Rate (2017-2027)
6.4. Plasma derived Coagulation Factor Concentrates
6.4.1. Global Plasma derived Coagulation Factor Concentrates Revenue and Growth Rate (2017-2027)
7. Hemophilia Treatment Drugs Market, By Distribution Channel
7.1. Introduction
7.2. Global Hemophilia Treatment Drugs Revenue and Market Share by Distribution Channel (2017-2027)
7.2.1. Global Hemophilia Treatment Drugs Revenue and Revenue Share by Distribution Channel (2017-2027)
7.3. Retail Pharmacies
7.3.1. Global Retail Pharmacies Revenue and Growth Rate (2017-2027)
7.4. Hospital Pharmacies
7.4.1. Global Hospital Pharmacies Revenue and Growth Rate (2017-2027)
7.5. Online Pharmacies
7.5.1. Global Online Pharmacies Revenue and Growth Rate (2017-2027)
8. Hemophilia Treatment Drugs Market, By Region
8.1. Introduction
8.2. Global Hemophilia Treatment Drugs Revenue and Market Share by Regions
8.2.1. Global Hemophilia Treatment Drugs Revenue by Regions (2017-2027)
8.3. North America Hemophilia Treatment Drugs by Countries
8.3.1. North America Hemophilia Treatment Drugs Revenue and Growth Rate (2017-2027)
8.3.2. North America Hemophilia Treatment Drugs Revenue (Million USD) by Countries (2017-2027)
8.3.3. United States
8.3.3.1. United States Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.4. Canada
8.3.4.1. Canada Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.5. Mexico
8.3.5.1. Mexico Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.4. Europe Hemophilia Treatment Drugs by Countries
8.4.1. Europe Hemophilia Treatment Drugs Revenue and Growth Rate (2017-2027)
8.4.2. Europe Hemophilia Treatment Drugs Revenue (Million USD) by Countries (2017-2027)
8.4.3. Germany
8.4.3.1. Germany Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.4. France
8.4.4.1. France Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.5. UK
8.4.5.1. UK Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.6. Russia
8.4.6.1. Russia Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.7. Italy
8.4.7.1. Italy Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.8. Rest of Europe
8.4.8.1. Rest of Europe Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.5. Asia-Pacific Hemophilia Treatment Drugs by Countries
8.5.1. Asia-Pacific Hemophilia Treatment Drugs Revenue and Growth Rate (2017-2027)
8.5.2. Asia-Pacific Hemophilia Treatment Drugs Revenue (Million USD) by Countries (2017-2027)
8.5.3. China
8.5.3.1. China Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.4. Japan
8.5.4.1. Japan Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.5. Korea
8.5.5.1. Korea Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.6. India
8.5.6.1. India Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.7. Southeast Asia
8.5.7.1. Southeast Asia Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.8. Rest of Asia-Pacific
8.5.8.1. Rest of Asia-Pacific Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.6. South America Hemophilia Treatment Drugs by Countries
8.6.1. South America Hemophilia Treatment Drugs Revenue and Growth Rate (2017-2027)
8.6.2. South America Hemophilia Treatment Drugs Revenue (Million USD) by Countries (2017-2027)
8.6.3. Brazil
8.6.3.1. Brazil Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.4. Argentina
8.6.4.1. Argentina Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.5. Columbia
8.6.5.1. Columbia Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.6. Rest of South America
8.6.6.1. Rest of South America Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7. Middle East and Africa Hemophilia Treatment Drugs by Countries
8.7.1. Middle East and Africa Hemophilia Treatment Drugs Revenue and Growth Rate (2017-2027)
8.7.2. Middle East and Africa Hemophilia Treatment Drugs Revenue (Million USD) by Countries (2017-2027)
8.7.3. Saudi Arabia
8.7.3.1. Saudi Arabia Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.4. United Arab Emirates
8.7.4.1. United Arab Emirates Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.5. Egypt
8.7.5.1. Egypt Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.6. Nigeria
8.7.6.1. Nigeria Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.7. South Africa
8.7.7.1. South Africa Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.8. Turkey
8.7.8.1. Turkey Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.9. Rest of Middle East and Africa
8.7.9.1. Rest of Middle East and Africa Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
9. Company Profiles
9.1. Bayer AG
9.1.1. Business Overview
9.1.2. Service Portfolio
9.1.3. Strategic Developments
9.1.4. Financial Overview
9.2. Swedish Orphan Biovitrum AB.
9.2.1. Business Overview
9.2.2. Service Portfolio
9.2.3. Strategic Developments
9.2.4. Financial Overview
9.3. Pfizer Inc.
9.3.1. Business Overview
9.3.2. Service Portfolio
9.3.3. Strategic Developments
9.3.4. Financial Overview
9.4. Biogen Idec, Inc.
9.4.1. Business Overview
9.4.2. Service Portfolio
9.4.3. Strategic Developments
9.4.4. Financial Overview
9.5. Baxter International Inc.
9.5.1. Business Overview
9.5.2. Service Portfolio
9.5.3. Strategic Developments
9.5.4. Financial Overview
10. Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.1. Global Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
10.2. Hemophilia Treatment Drugs Market Forecast by Regions (2017-2027)
10.2.1. North America Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.1.1. United States Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.1.2. Canada Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.1.3. Mexico Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.2. Europe Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.2.1. Germany Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.2.2. France Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.2.3. UK Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.2.4. Russia Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.2.5. Italy Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.2.6. Rest of Europe Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.3. Asia-Pacific Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.3.1. China Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.3.2. Japan Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.3.3. Korea Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.3.4. India Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.3.5. Southeast Asia Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.3.6. Rest of Asia-Pacific Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.4. South America Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.4.1. Brazil Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.4.2. Argentina Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.4.3. Columbia Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.4.4. Rest of South America Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.5. Middle East and Africa Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.5.1. Saudi Arabia Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.5.2. United Arab Emirates Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.5.3. Egypt Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.5.4. Nigeria Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.5.5. South Africa Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.5.6. Turkey Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.2.5.7. Rest of Middle East and Africa Hemophilia Treatment Drugs Market Forecast (2017-2027)
10.3. Hemophilia Treatment Drugs Market Forecast by Disease Indication (2017-2027)
10.3.1. Hemophilia Treatment Drugs Forecast by Disease Indication (2017-2027)
10.3.2. Hemophilia Treatment Drugs Market Share Forecast by Disease Indication (2017-2027)
10.4. Hemophilia Treatment Drugs Market Forecast by Product Type (2017-2027)
10.4.1. Hemophilia Treatment Drugs Forecast by Product Type (2017-2027)
10.4.2. Hemophilia Treatment Drugs Market Share Forecast by Product Type (2017-2027)
10.5. Hemophilia Treatment Drugs Market Forecast by Distribution Channel (2017-2027)
10.5.1. Hemophilia Treatment Drugs Forecast by Distribution Channel (2017-2027)
10.5.2. Hemophilia Treatment Drugs Market Share Forecast by Distribution Channel (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Hemophilia Treatment Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Hemophilia Treatment Drugs Revenue and Revenue Share by Disease Indication (2017-2018)
Figure Global Hemophilia A Revenue and Growth Rate (2017-2018)
Figure Global Hemophilia B Revenue and Growth Rate (2017-2018)
Figure Global Other Revenue and Growth Rate (2017-2018)
Table Global Hemophilia Treatment Drugs Revenue and Revenue Share by Product Type (2017-2018)
Figure Global Recombinant Coagulation Factor Concentrates Revenue and Growth Rate (2017-2018)
Figure Global Plasma derived Coagulation Factor Concentrates Revenue and Growth Rate (2017-2018)
Table Global Hemophilia Treatment Drugs Revenue and Revenue Share by Distribution Channel (2017-2018)
Figure Global Retail Pharmacies Revenue and Growth Rate (2017-2018)
Figure Global Hospital Pharmacies Revenue and Growth Rate (2017-2018)
Figure Global Online Pharmacies Revenue and Growth Rate (2017-2018)
Table Global Hemophilia Treatment Drugs Revenue by Regions (2017-2018)
Figure North America Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure North America Hemophilia Treatment Drugs Revenue and Growth Rate (2017-2018)
Figure North America Hemophilia Treatment Drugs by Countries (2017-2018)
Figure North America Hemophilia Treatment Drugs Revenue (Million USD) by Countries (2017-2018)
Figure United States Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure United States Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure Canada Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure Mexico Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure Europe Hemophilia Treatment Drugs Revenue and Growth Rate (2017-2018)
Figure Europe Hemophilia Treatment Drugs by Countries (2017-2018)
Figure Europe Hemophilia Treatment Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Germany Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure Germany Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure France Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure UK Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure Russia Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure Italy Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure Rest of Europe Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure Asia-Pacific Hemophilia Treatment Drugs Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Hemophilia Treatment Drugs by Countries (2017-2018)
Figure Asia-Pacific Hemophilia Treatment Drugs Revenue (Million USD) by Countries (2017-2018)
Figure China Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure China Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure Japan Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure Korea Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure India Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure Southeast Asia Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure South America Hemophilia Treatment Drugs Revenue and Growth Rate (2017-2018)
Figure South America Hemophilia Treatment Drugs by Countries (2017-2018)
Figure South America Hemophilia Treatment Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure Brazil Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure Argentina Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure Columbia Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure Rest of South America Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure Middle East and Africa Hemophilia Treatment Drugs Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Hemophilia Treatment Drugs by Countries (2017-2018)
Figure Middle East and Africa Hemophilia Treatment Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure Saudi Arabia Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure United Arab Emirates Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure Egypt Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure Nigeria Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure South Africa Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure Turkey Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Hemophilia Treatment Drugs Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Table Bayer AG Hemophilia Treatment Drugs Financial Overview
Table Swedish Orphan Biovitrum AB. Hemophilia Treatment Drugs Financial Overview
Table Pfizer Inc. Hemophilia Treatment Drugs Financial Overview
Table Biogen Idec, Inc. Hemophilia Treatment Drugs Financial Overview
Table Baxter International Inc. Hemophilia Treatment Drugs Financial Overview
Figure Global Hemophilia Treatment Drugs Revenue (Millions USD) and Growth Rate (2018-2025)
Table Hemophilia Treatment Drugs Market Forecast by Regions (2018-2025)
Figure North America Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure United States Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure Canada Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure Mexico Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure Europe Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure Germany Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure France Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure UK Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure Russia Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure Italy Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure Rest of Europe Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure Asia-Pacific Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure China Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure Japan Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure Korea Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure India Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure Southeast Asia Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure South America Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure Brazil Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure Argentina Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure Columbia Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure Rest of South America Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure Middle East and Africa Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure Saudi Arabia Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure United Arab Emirates Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure Egypt Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure Nigeria Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure South Africa Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure Turkey Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Hemophilia Treatment Drugs Market Forecast (2018-2025)
Figure Global Hemophilia Treatment Drugs Forecast by Disease Indication (2018-2025)
Figure Global Hemophilia Treatment Drugs Market Share Forecast by Disease Indication (2018-2025)
Figure Global Hemophilia Treatment Drugs Forecast by Disease Indication (2018-2025)
Figure Global Hemophilia Treatment Drugs Forecast by Product Type (2018-2025)
Figure Global Hemophilia Treatment Drugs Market Share Forecast by Product Type (2018-2025)
Figure Global Hemophilia Treatment Drugs Forecast by Product Type (2018-2025)
Figure Global Hemophilia Treatment Drugs Forecast by Distribution Channel (2018-2025)
Figure Global Hemophilia Treatment Drugs Market Share Forecast by Distribution Channel (2018-2025)
Figure Global Hemophilia Treatment Drugs Forecast by Distribution Channel (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|